Take Solutions Ltd

Take Solutions Ltd

₹ 18.1 2.26%
02 Jun - close price
About

Founded in 2001 as a software services provider, TAKE is currently a technology driven, full service Clinical Research Organization. It helps biopharma companies throughout the drug development process, and beyond. Headquartered in Chennai, India, it has a global footprint spanning the Americas, Europe and the Asia Pacific region.
The co. delivers domain-intensive services in Life Sciences.
TAKE is the only full-service technology-driven Clinical Research Organization listed in India.
It has 1,70,000 regulatory submissions and submitted 5% of all regulatory submissions to USFDA 2012 to 2020.[1] [1] [2] [3]

Key Points

Services Offering
Life Sciences: The Company offers clients a unique combination of full-service Clinical Research, Generics Development, Data Sciences, Regulatory Affairs, and Pharmacovigilance/Safety services backed by distinctive technology expertise. [1]

  • Market Cap 268 Cr.
  • Current Price 18.1
  • High / Low 29.6 / 12.7
  • Stock P/E
  • Book Value 7.34
  • Dividend Yield 0.00 %
  • ROCE -13.9 %
  • ROE -25.7 %
  • Face Value 1.00

Pros

  • Company has reduced debt.
  • Debtor days have improved from 103 to 58.0 days.
  • Company's working capital requirements have reduced from 118 days to 20.4 days

Cons

  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of -34.7% over past five years.
  • Company has a low return on equity of -49.0% over last 3 years.
  • Contingent liabilities of Rs.97.9 Cr.
  • Promoter holding has decreased over last 3 years: -13.5%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Miscellaneous Industry: Miscellaneous

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023
371 166 171 216 221 209 197 207 41 58 45 51 38
526 212 248 211 179 178 174 225 69 61 72 55 27
Operating Profit -155 -46 -77 5 42 31 24 -18 -28 -3 -27 -4 11
OPM % -42% -28% -45% 2% 19% 15% 12% -8% -68% -5% -60% -8% 29%
16 -153 3 10 -68 3 2 9 -690 -16 25 1 -59
Interest 10 10 9 9 8 11 8 9 2 2 1 1 4
Depreciation 40 30 29 28 28 25 26 23 5 6 5 4 4
Profit before tax -190 -240 -113 -23 -62 -3 -7 -41 -725 -27 -8 -8 -56
Tax % 16% -0% -3% -13% -10% -28% -22% -3% -0% 2% 0% -31% 0%
Net Profit -159 -241 -116 -25 -68 -3 -9 -42 -725 -26 -8 -10 -56
EPS in Rs -10.68 -16.36 -7.81 -1.72 -4.60 -0.22 -0.60 -2.83 -48.99 -1.77 -0.54 -0.69 -3.78
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
704 832 816 730 1,030 1,345 1,587 2,039 2,213 774 655 189
559 670 668 581 817 1,082 1,281 1,655 2,044 847 648 208
Operating Profit 145 161 147 149 213 262 307 384 169 -73 7 -19
OPM % 21% 19% 18% 20% 21% 20% 19% 19% 8% -9% 1% -10%
15 7 6 8 21 13 6 11 26 -211 -677 -55
Interest 18 14 14 13 15 23 21 25 41 37 29 7
Depreciation 27 46 77 60 74 87 104 154 167 115 80 17
Profit before tax 115 107 63 85 145 165 188 216 -13 -437 -779 -99
Tax % 18% 17% 2% 6% 14% 11% 15% 17% 15% -3% -0% -2%
Net Profit 94 89 62 80 125 146 160 178 -11 -450 -782 -100
EPS in Rs 6.99 6.49 4.74 5.71 9.78 10.74 10.85 11.99 -0.84 -30.56 -52.88 -6.78
Dividend Payout % 14% 15% 21% 17% 10% 9% 15% 8% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: -14%
5 Years: -35%
3 Years: -56%
TTM: -71%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 95%
Stock Price CAGR
10 Years: -5%
5 Years: -40%
3 Years: -33%
1 Year: -25%
Return on Equity
10 Years: -4%
5 Years: -17%
3 Years: -49%
Last Year: -26%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
12 12 12 12 12 13 15 15 15 15 15 15
Reserves 330 408 458 512 619 898 1,314 1,504 1,561 1,110 166 94
193 196 207 209 336 237 323 474 553 514 59 46
206 220 185 189 246 221 189 339 336 187 984 69
Total Liabilities 741 837 862 922 1,214 1,369 1,840 2,331 2,465 1,826 1,223 224
339 368 384 359 543 554 589 1,091 1,234 934 101 74
CWIP 1 3 2 17 3 21 42 41 1 0 3 10
Investments 50 50 50 6 21 10 59 10 18 7 0 0
351 415 426 541 647 785 1,150 1,188 1,213 885 1,119 140
Total Assets 741 837 862 922 1,214 1,369 1,840 2,331 2,465 1,826 1,223 224

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
115 117 100 74 151 56 121 104 211 135 30
-81 -70 -91 -14 -292 -130 -179 -474 -233 -57 15
-21 -31 -7 -11 111 56 302 100 21 -84 -55
Net Cash Flow 13 16 2 49 -30 -18 243 -270 -2 -6 -10

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 82 99 100 120 107 118 108 94 116 205 45 58
Inventory Days 3
Days Payable 104
Cash Conversion Cycle 82 99 100 120 107 118 108 94 116 205 45 -42
Working Capital Days 55 71 83 121 107 136 143 142 137 289 45 20
ROCE % 26% 21% 12% 14% 17% 17% 15% 13% 1% -9% -6% -14%

Shareholding Pattern

Numbers in percentages

Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023
58.65 53.41 53.41 53.41 53.41 53.41 53.41 53.41 53.41 53.41 53.41 53.41
9.61 4.62 1.92 1.72 1.61 1.55 1.38 0.84 0.75 0.41 0.13 0.13
2.03 1.35 1.14 1.13 0.27 0.28 0.28 0.28 0.04 0.00 0.00 0.00
29.72 40.62 43.53 43.74 44.71 44.76 44.93 45.47 45.80 46.19 46.44 46.45

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls